Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Teva names new CFO and bulks up its opioid liability fund - PMLiVE
First generic version of Teva's Copaxone cleared by FDA - PMLiVE
Teva and Active Biotech Expand Investigational MS Treatment Program
What are the implications of a generic Teva MS drug? Here's what the wags say - STAT
World MS Day, May 31, Marked by Teva's 'Life Moments with MS' Social Media Campaign
FDA Nod to New MS Drug Spells Trouble for Teva - Haaretz Com - Haaretz.com
Teva | Partnership | Direct Relief
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
FDA Delays Ruling on Teva Petition Against Generic Copaxone for MS
PTAB invalidates three patents covering Teva's Copaxone, opens door for Mylan's generic version - IPWatchdog.com | Patents & Intellectual Property Law
Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions
US regulator backs copycat version of Teva MS drug
Teva and BioGen Locked in Dispute Over MS Drug Agreement | New Jersey Law Journal
Teva loses key MS drug patent | Nature Reviews Drug Discovery
Better Late Than Never: Novartis, Momenta Win FDA Approval for Delayed MS Drug | BioSpace
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
U.S. court ruling on MS drug is the latest blow for Teva | Reuters
BCBS of Vermont sues Teva Pharmaceuticals over marketing for its MS drug Copaxone
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva steps up defence of key MS drug
Federal Judge, Clarifying FCA Causation, Grants Feds Partial Summary Judgment | Law.com
